Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
Enriqueta Felip(Institut Català d'Ornitologia), Heather A. Wakelee(Palo Alto Institute), Mark L. McCleland(Revolution Medicines (United States)), Hirotsugu Kenmotsu(Shizuoka Cancer Center), Yuh‐Min Chen(National Yang Ming Chiao Tung University), Caicun Zhou(Tongji University), Nasser K. Altorki(Cornell University), Barbara J. Gitlitz(University of Southern California), Ihor Vynnychenko(Sumy State University), Fan Wu(Roche (China)), Alexander Luft(Leningrad Regional Cancer Center), Tibor Csőszi, А. Л. Акопов(First Pavlov State Medical University of St. Petersburg), Yu Deng(Capital Medical University), Shunichi Sugawara(Sendai Kousei Hospital), David Voong, Jing Yi(Yantai University), Elizabeth Bennett, Antonio Chella(Azienda Ospedaliera Universitaria Pisana), Oleksandr Goloborodko(National University Zaporizhzhia Polytechnic), Alex Martínez‐Martí(Vall d'Hebron Hospital Universitari)
Cited by 1,475
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k